Lupin is currently trading at Rs. 2232.00, up by 23.05 points or 1.04% from its previous closing of Rs. 2208.95 on the BSE.
The scrip opened at Rs. 2231.30 and has touched a high and low of Rs. 2247.15 and Rs. 2220.45 respectively. So far 3960 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1091.80 on 22-Sep-2023.
Last one week high and low of the scrip stood at Rs. 2298.10 and Rs. 2185.25 respectively. The current market cap of the company is Rs. 101983.20 crore.
The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 46.10% and 6.92% respectively.
Lupin has signed Share Subscription & Shareholders agreement with Sunsure Solarpark Seventeen (Sunsure Solarpark) and Sunsure Energy (Sunsure) to make equity investment in Sunsure Solarpark. The objective of investment is to purchase renewable power through open access for the Company’s Tarapur manufacturing site. In addition to saving on power costs, the acquisition would enable the Company to fulfill its commitments on decarbonization.
Upto 42.61% of equity share capital of Sunsure Solarpark to be acquired at a total consideration not exceeding Rs 10.55 crore, to be completed in two tranches, in the capacity as a Captive User.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |